Advertisement

Renal Involvement in Chagas’ Disease (American Trypanosomiasis)

  • Elizabeth De Francesco Daher
  • Geraldo Bezerra da Silva JuniorEmail author
  • Elvino Barros
  • Verônica Verleine Hörbe Antunes
Chapter
  • 28 Downloads

Abstract

Chagas disease is caused by the protozoa Trypanosoma cruzi, in which kidney injury is rarely described. The aim of this study is to describe the features of kidney injury in Chagas disease. This is a review study regarding kidney injury associated with Chagas disease. A deep search was performed in the main medical databases (PubMed and Scielo), using the keywords “Chagas disease” and “Kidney.” Renal involvement is a rare manifestation of Chagas’ disease, and there are few studies on the subject in literature. There is evidence of functional and structural renal alterations after T. cruzi infection. The occurrence of glomerulonephritis in the chronic phase of the disease has been reported in infections by T. cruzi. The pathophysiology of renal involvement in Chagas disease seems to include autoimmune phenomena. T. cruzi antigens have also been identified in renal graft glomeruli and interstitium in a patient with acute form of the Chagas disease. The most common lesions associated with the trypanosomes are mesangial proliferative glomerulonephritis and membranoproliferative glomerulonephritis. The specific treatment aims to cure the infection, prevent organ lesions or their progress, and decrease the possibility of T. cruzi transmission, being effective in most cases. Renal function deterioration is observed in patients with Chagas disease, but there is no currently consistent data demonstrating renal function recovery after specific treatment. Further studies are required to better investigate renal involvement in Chagas disease.

Keywords

Chagas disease Trypanosoma cruzi Membranoproliferative glomerulonephritis Acute kidney injury Neglected diseases 

References

  1. 1.
    Maguire JH. Trypanosoma. In: Gorbach S, Bartlett J, Blacklow N, editors. Infectious diseases. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins; 2004. p. 2327–34.Google Scholar
  2. 2.
    Teixeira ARL, Nascimento R, Sturm NR. Evolution and pathology in Chagas disease - a review. Mem Inst Oswaldo Cruz. 2006;101(5):463–91.CrossRefGoogle Scholar
  3. 3.
    Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391:82–94.CrossRefGoogle Scholar
  4. 4.
    Beltrão HB, Cerroni MP, Freitas DR, et al. Investigation of two outbreaks of suspected oral transmission of acute Chagas disease in the Amazon region, Para State, Brazil, in 2007. Trop Dr. 2009;39(4):231–2.CrossRefGoogle Scholar
  5. 5.
    Riarte A, Luna C, Sabatiello R, et al. Chagas’ disease in patients with kidney transplants: 7 years of experience 1989-1996. Clin Infect Dis. 1999;29:561–7.CrossRefGoogle Scholar
  6. 6.
    Bem C, Martin DL, Gilman RH. Acute and congenital Chagas disease. Adv Parasitol. 2011;75:19–47.CrossRefGoogle Scholar
  7. 7.
    Centers for Disease Control and Prevention (CDC). Chagas disease after organ transplantation--United States, 2001. MMWR Morb Mortal Wkly Rep. 2002;51:210–2.Google Scholar
  8. 8.
    Kun H, Moore A, Mascola L, et al. Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis. 2009;48:1534–40.CrossRefGoogle Scholar
  9. 9.
    Silva Junior GB, Antunes VVH, Motta M, Barros EJG, Daher EF. Chagas disease-associated kidney injury – a review. Nefrol Latinoam. 2017;14(1):22–6.CrossRefGoogle Scholar
  10. 10.
    Kirchhoff LV. American trypanosomiasis (Chagas’ disease) – a tropical disease now in the United States. N Engl J Med. 1993;329:639–44.CrossRefGoogle Scholar
  11. 11.
    Dias JCP. Globalization, inequity and Chagas disease. Cad Saúde Pública (Rio de Janeiro). 2007;23:S13–22.CrossRefGoogle Scholar
  12. 12.
    Vinhaes MC, Dias JCD. Doença de Chagas no Brasil. Cad Saúde Pública (Rio de Janeiro). 2000;16(Supp. 2):7–12.CrossRefGoogle Scholar
  13. 13.
    Cardoso AVN, Lescano SAZ, Amato Neto V, Gakiya E, Santos SIV. Survival of Trypanosoma Cruzi in sugar cane used to prepare juice. Rev Inst Med Trop Sao Paulo. 2006;48(5):287–9.CrossRefGoogle Scholar
  14. 14.
    Bastos CJC, Aras R, Mota G, Reis F, Dias JP, Jesus RS, Freire MS, Araújo EG, Prazeres J, Grassi MF. Clinical outcomes of thirteen patients with acute Chagas disease acquired through oral transmission from two urban outbreaks in northeastern Brazil. PLoS Negl Trop Dis. 2010;4(6):e711.CrossRefGoogle Scholar
  15. 15.
    Dias JCP, Ramos Junior AN, Gontijo ED, Luquetti A, Shikanai-Yasuda MA, Coura JR, et al. II Consenso Brasileiro em Doença de Chagas, 2015. Epidemiol Serv Saúde. 2016;25(n.spe):7–86.PubMedGoogle Scholar
  16. 16.
    Andrade ZA. Patologia da Doença de Chagas (Portuguese). In: Brener Z, Andrade ZA, Barral-Netto M, editors. Trypanosoma cruzi e Doença de Chagas. 2nd ed. Rio de Janeiro: Guanabara Koogan; 2000. p. 201–30.Google Scholar
  17. 17.
    Tarleton RL. Chagas disease: a role for autoimmunity? Trends Parasitol. 2003;19(10):447–51.CrossRefGoogle Scholar
  18. 18.
    Hyland KV, Engman DM. Further thoughts on where we stand on the autoimmunity hypothesis of Chagas disease. Trends Parasitol. 2006;22(3):101–2.CrossRefGoogle Scholar
  19. 19.
    Coura JR. Chagas disease: what is known and what is needed – a background article. Mem Inst Oswaldo Cruz (Rio de Janeiro). 2007;102:113–22.CrossRefGoogle Scholar
  20. 20.
    Cumbinho LC, Pizzini CC, Oliveira FS, Batista W, Oliveira GM. Cardiorenal interaction during the acute phase of experimental Trypanosoma cruzi infection: the influence of aldosterone and the AT1 receptor on mortality. J Exp Integr Med. 2012;2(3):199–206.CrossRefGoogle Scholar
  21. 21.
    Pinto AY, Valente SA, Valente VC. Emerging acute Chagas disease in Amazonian Brazil: case reports with serious cardiac involvement. Braz J Infect Dis. 2004;8:454–60.CrossRefGoogle Scholar
  22. 22.
    Lemos JRD, Rodrigues WF, Miguel CB, Parreira RC, Miguel RB, Rogerio AP, et al. Influence os parasite load on renal function in mice acutely infected with Trypanosoma cruzi. PLoS One. 2013;8(8):e71772.CrossRefGoogle Scholar
  23. 23.
    Costa RS, Monteiro RC, Lehuen A, Joskowicz M, Noël LH, Droz D. Immune complex-mediated glomerulopathy in experimental Chagas’ disease. Clin Immunol Immunopathol. 1991;58:102–14.CrossRefGoogle Scholar
  24. 24.
    Oliveira GM, da Silva TM, Batista WS, Franco M, Schor N. Acute Trypanosoma cruzi experimental infection induced renal ischemic/reperfusion lesion in mice. Parasitol Res. 2009;106:111–20.CrossRefGoogle Scholar
  25. 25.
    Oliveira GM, Masuda MO, Rocha NN, Schor N, Hooper CS, Araújo-Jorge TC, Henriques-Pons A. Absence of Fas-L aggravates renal injury in acute Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz. 2009;104:1063–71.CrossRefGoogle Scholar
  26. 26.
    Bruijn JA, Oemar BS, Ehrich JH, Oemar BS, Ehrich JM. Anti-basement membrane glomerulopathy in experimental trypanosomiasis. J Immunol. 1987;139:2482–8.PubMedGoogle Scholar
  27. 27.
    van Velthuysen MLF, Bruijn JA, van Leer EHG, Fleuren GJ. Pathogenesis of trypanosomiasis-induced glomerulonephritis in mice. Nephrol Dial Transplant. 1992;7:507–15.PubMedGoogle Scholar
  28. 28.
    Rickman WJ, Cox HW. Association of autoantibodies with anemia, splenomegaly, and glomerulonephritis in experimental African trypanosomiasis. J Parasitol. 1979;65:65–73.CrossRefGoogle Scholar
  29. 29.
    Arias LF, Duque E, Ocampo C, et al. Detection of amastigotes of Trypanosoma cruzi in a kidney graft with acute dysfunction. Transplant Proc. 2006;38:885–7.CrossRefGoogle Scholar
  30. 30.
    Silva AE, Silva AC, Faleiros AC, et al. Acute Chagas’ disease in postrenal transplant and treatment with benzonidazole. Ann Diagn Pathol. 2010;14:199–203.CrossRefGoogle Scholar
  31. 31.
    Mohallem SV, Ramos SG, dos Reis MA, Seabra DD, Teixeira VP. Prevalence of renal infarcts in autopsies of chronic Chagas disease patients. Rev Soc Bras Med Trop. 1996;29:571–4.CrossRefGoogle Scholar
  32. 32.
    Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Coordenação-Geral de Desenvolvimento da Epidemiologia em Serviços. Guia de Vigilância em Saúde. 1st ed. Brasília: Ministério da Saúde; 2017.Google Scholar
  33. 33.
    Coura JR, Borges-Pereira J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz. 2011;106(6):641–5.CrossRefGoogle Scholar
  34. 34.
    Viotti R, Alarcón de Noya B, Araujo-Jorge T, et al. Towards a paradigma shift in treatment of chronic Chagas disease. Antimicrob Agents Chemother. 2014;58(2):635–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Elizabeth De Francesco Daher
    • 1
  • Geraldo Bezerra da Silva Junior
    • 2
    Email author
  • Elvino Barros
    • 3
  • Verônica Verleine Hörbe Antunes
    • 4
  1. 1.Post-Graduation Program in Medical Sciences, School of MedicineFederal University of CearaFortalezaBrazil
  2. 2.Post-Graduation Programs in Public Health and Medical Sciences, School of MedicineUniversity of FortalezaFortalezaBrazil
  3. 3.School of MedicineFederal University of Rio Grande do SulPorto AlegreBrazil
  4. 4.Division of NephrologyHospital de Clinicas de Porto Alegre, Federal University of Rio Grande do SulPorto AlegreBrazil

Personalised recommendations